Payment overview · 2025
General Payments
$589.19
31 reported records · 14 companies
Healthcare provider profile · identity verified
Antonio Wong, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EDINBURG, TX · NPI 1932206315
Verified facts
What the public records show
CMS Open Payments records show Antonio Wong, MD received $589.19 in general payments during 2025 across 31 reported records.
GlaxoSmithKline, LLC. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 394 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 394 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $153.29 | 26.0% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.95 | 17.3% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.67 | 8.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.85 | 8.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.31 | 7.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.67 | 6.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.69 | 4.9% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $22.17 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.19 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.39 | 3.1% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $17.55 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.85 | 2.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.62 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.99 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $589.19 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $153.29 | 9 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $119.50 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $67.61 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $48.67 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.85 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.85 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.68 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.69 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 99 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 181 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 394 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 97 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 145 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
97 | 45 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
181 | 58 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
394 | 108 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
97 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
394 | 108 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
145 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
374 | 100 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1553 | 524 |
| Metformin Hcl | Metformin Hcl | 690 | 237 |
| Levothyroxine Sodium | Levothyroxine Sodium | 625 | 178 |
| Metoprolol Succinate | Metoprolol Succinate | 613 | 197 |
| Losartan Potassium | Losartan Potassium | 598 | 195 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 594 | 186 |
| Lisinopril | Lisinopril | 590 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 474 | 162 |
| Jardiance | Empagliflozin | 394 | 108 |
| Ozempic | Semaglutide | 374 | 100 |
| Omeprazole | Omeprazole | 364 | 124 |
| Montelukast Sodium | Montelukast Sodium | 344 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 136 |
| Hydrochlorothiazide | Hydrochlorothiazide | 336 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 296 | 105 |
| Simvastatin | Simvastatin | 294 | 99 |
| Gabapentin | Gabapentin | 282 | 113 |
| Furosemide | Furosemide | 256 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 252 | 81 |
| Alendronate Sodium | Alendronate Sodium | 244 | 83 |
| Duloxetine Hcl | Duloxetine Hcl | 220 | 80 |
| Glipizide | Glipizide | 195 | 64 |
| Farxiga | Dapagliflozin Propanediol | 181 | 58 |
| Baclofen | Baclofen | 179 | 80 |
| Naproxen | Naproxen | 166 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 56 |
| Alprazolam | Alprazolam | 155 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 149 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 146 | 49 |
| Mounjaro | Tirzepatide | 145 | 37 |
| Ezetimibe | Ezetimibe | 133 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 43 |
| Fenofibrate | Fenofibrate Nanocrystallized | 130 | 40 |
| Nabumetone | Nabumetone | 129 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 57 |
| Spironolactone | Spironolactone | 105 | 37 |
| Nifedipine Er | Nifedipine | 103 | 42 |
| Donepezil Hcl | Donepezil Hcl | 102 | 39 |
| Famotidine | Famotidine | 101 | 35 |
| Lovastatin | Lovastatin | 101 | 33 |
| Eliquis | Apixaban | 99 | 28 |
| Linzess | Linaclotide | 97 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 41 |
| Januvia | Sitagliptin Phosphate | 88 | 32 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 87 | 35 |
| Fenofibrate | Fenofibrate,micronized | 86 | 26 |
| Tresiba Flextouch U-100 | Insulin Degludec | 86 | 39 |
| Azithromycin | Azithromycin | 85 | 81 |
| Potassium Chloride | Potassium Chloride | 81 | 31 |
| Tresiba Flextouch U-200 | Insulin Degludec | 81 | 26 |
| Myrbetriq | Mirabegron | 80 | 28 |
| Mirtazapine | Mirtazapine | 79 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 27 |
| Carvedilol | Carvedilol | 76 | 26 |
| Ibuprofen | Ibuprofen | 75 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 26 |
| Meloxicam | Meloxicam | 71 | 36 |
| Fenofibrate | Fenofibrate | 70 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 25 |
| Folic Acid | Folic Acid | 68 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 23 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 23 |
| Finasteride | Finasteride | 66 | 29 |
| Memantine Hcl | Memantine Hcl | 66 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 27 |
| Xarelto | Rivaroxaban | 64 | 21 |
| Prednisone | Prednisone | 63 | 56 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 20 |
| Allopurinol | Allopurinol | 60 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 18 |
| Trulicity | Dulaglutide | 58 | 16 |
| Gemfibrozil | Gemfibrozil | 56 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 35 |
| Atenolol | Atenolol | 54 | 18 |
| Enalapril Maleate | Enalapril Maleate | 54 | 25 |
| Trazodone Hcl | Trazodone Hcl | 54 | 21 |
| Valsartan | Valsartan | 54 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 30 |
| Clonidine Hcl | Clonidine Hcl | 49 | 24 |
| Single Use Swab | Alcohol Antiseptic Pads | 49 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 21 |
| Metformin Hcl Er | Metformin Hcl | 48 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 46 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 36 |
| Irbesartan | Irbesartan | 45 | 14 |
| Pregabalin | Pregabalin | 45 | 16 |
| Meclizine Hcl | Meclizine Hcl | 44 | 29 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 44 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 42 | 13 |
| Tramadol Hcl | Tramadol Hcl | 42 | 19 |
| Telmisartan | Telmisartan | 39 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 37 | 16 |
| Fluconazole | Fluconazole | 35 | 27 |
| Sertraline Hcl | Sertraline Hcl | 35 | 18 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 12 |
| Hydrocortisone | Hydrocortisone | 32 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Cilostazol | Cilostazol | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 14 |
| Vascepa | Icosapent Ethyl | 30 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | 11 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 21 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 20 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Nystatin | Nystatin | 17 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Prolia | Denosumab | 14 | 11 |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $589.19 · 31 records | GlaxoSmithKline, LLC. | AREXVY, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, REXULTI, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, XIFAXAN, Xhance, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error